Delcath Systems: Filtering Through Its Past & Future
Impossible d'ajouter des articles
Échec de l’élimination de la liste d'envies.
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Delcath Systems: Filtering Through Its Past & Future
-
Lu par :
-
De :
À propos de ce contenu audio
An interview with Gerard Michel, CEO of Delcath Systems, where Gerard reflects back on his time with Vericel, the decision to become CEO of Delcath, the initial NDA submission for the HEPZATO™ KIT, and the preliminary data release from the Phase 3 FOCUS study. Gerard also addresses the future for Delcath, including the impending full Phase 3 FOCUS results, future clinical indications to be pursued with the HEPZATO™ KIT, and commercial dynamics in the interventional oncology space.
Companies discussed during the podcast:
Delcath Systems, Inc (Nasdaq: DCTH)
Vericel Corporation (Nasdaq: VCEL)
Immunocore Ltd (Nasdaq: IMCR)
Bright Minds Biosciences (OTCQB: BMBIF, CSE: DRUG)
Gerard Michel, CEO of Delcath Systems, Inc. (“Delcath”) appeared on this episode of the podcast. Listeners are urged to review Delcath’s SEC filings and cautioned not to place undue reliance on any forward-looking statements. Delcath undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.
Vous êtes membre Amazon Prime ?
Bénéficiez automatiquement de 2 livres audio offerts.Bonne écoute !
